The exit strategies of life sciences companies have become more varied due to the current situation being experienced by global capital markets. This is primarily the case for German life sciences companies as well. The choice of exit scenario must be made carefully based on the individual circumstances of the company. The panelists will present and discuss the different exit variations and commercialization strategies, specifically when considering exits of German life sciences companies in other countries (such as the United States or Switzerland)
Collaboration Deals
Joint Ventures
Staged Exits
Milestone Agreements
Indemnification vs. Warranties
Sub-licensing structures
Big pharma deal terms
Speakers:
Sven Riethmueller (Attorney, member of New York and Massachusetts Bars), Foley & Lardner LLP
Dr. Irina Staatz-Granzer, Staatz Business Development and Strategy
Professor Dr. Christof Hettich (Rechtsanwalt), Rittershaus
Related Insights
06 March 2025
Events
SEC Enforcement Landscape: Lessons and Trends for Advisers
The SEC Enforcement program continues to aggressively pursue advisers on all fronts. This panel will discuss lessons from recent enforcement actions and insight into agency priorities that adviser legal and compliance personnel can incorporate into their firms’ compliance programs. Foley Partner Jim Lundy will moderate.
13 February 2025
Energy Current
Texas’ Power Transmission Infrastructure: Addressing Growing Demand from Data Centers and Crypto Mining
Texas is facing a rapidly evolving energy landscape, driven in part by the surging power demands of data centers and cryptocurrency mining operations.
13 February 2025
Blogs
Foley Kicks Off 2025 at Infocast Projects & Money: Industry Insights and Policy Predictions
A large number of key players in the renewable energy industry kicked off their 2025 in New Orleans, Louisiana for the Annual Infocast Projects & Money conference.